| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ISRG | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -11.3K | -100% | $0.00* | 0 | Feb 28, 2024 | Common Stock | 11.3K | $77.00 | Direct | F7 |
| transaction | ISRG | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -22.5K | -100% | $0.00* | 0 | Feb 28, 2024 | Common Stock | 22.5K | $79.64 | Direct | F8 |
| transaction | ISRG | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -22.5K | -100% | $0.00* | 0 | Feb 28, 2024 | Common Stock | 22.5K | $109.49 | Direct | F7 |
| transaction | ISRG | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -12.8K | -100% | $0.00* | 0 | Feb 28, 2024 | Common Stock | 12.8K | $139.52 | Direct | F8 |
| transaction | ISRG | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -10.5K | -100% | $0.00* | 0 | Feb 28, 2024 | Common Stock | 10.5K | $166.62 | Direct | F7 |
| transaction | ISRG | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -12.8K | -100% | $0.00* | 0 | Feb 28, 2024 | Common Stock | 12.8K | $174.26 | Direct | F7 |
| transaction | ISRG | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -13.5K | -100% | $0.00* | 0 | Feb 28, 2024 | Common Stock | 13.5K | $177.99 | Direct | F8 |
| transaction | ISRG | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -10.5K | -100% | $0.00* | 0 | Feb 28, 2024 | Common Stock | 10.5K | $182.83 | Direct | F8 |
| transaction | ISRG | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -13.5K | -100% | $0.00* | 0 | Feb 28, 2024 | Common Stock | 13.5K | $242.34 | Direct | F7 |
| transaction | ISRG | Restricted Stock Units | Options Exercise | $0 | -2.25K | -100% | $0.00* | 0 | Feb 29, 2024 | Common Stock | 2.25K | $0.00 | Direct | F9 |
| transaction | ISRG | Restricted Stock Units | Options Exercise | $0 | -1K | -33.36% | $0.00 | 2K | Feb 29, 2024 | Common Stock | 1K | $0.00 | Direct | F9 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | These shares were sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on November 15, 2024. |
| F2 | The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $383.56 to $386.01 as follows: 9,629 shares sold at $383.56 to $384.54; 57,452 shares sold at $384.59 to $385.59; and 6,479 shares sold at $385.61 to $386.01. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| F3 | The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $383.85 to $385.97 as follows: 3,620 shares sold at $383.85 to $384.82; 10,760 shares sold at $384.87 to $385.85; and 240 shares sold at $385.90 to $386.01. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $383.85 to $385.97 as follows: 3,390 shares sold at $383.85 to $384.82; 10,116 shares sold at $384.87 to $385.79; and 244 shares sold at $385.90 to $385.97. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $383.85 to $385.97 as follows: 1,574 shares sold at $383.85 to $384.73; 5,144 shares sold at $384.87 to $385.79; and 142 shares sold at $385.90 to $385.97. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| F6 | RSUs vest 25% per year over a four year period, commencing on the first anniversary of the grant date. RSUs convert into common stock on the vest date on a one-for-one basis. 25 % of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account. |
| F7 | Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter. |
| F8 | Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter. |
| F9 | Each RSU granted represents a contingent right to receive one share of Intuitive Surgical common stock. The grant vests 25% on the first anniversary of the date of grant and annually thereafter, over a four year period. |